|By Scott Matusow, @scottmatusow|
|Tuesday, 19 February 2013 06:52|
DARA Biosciences (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and cialis en mexico oncology supportive care products, is expecting to hear soon on the buy sildenafil status of its Orphan Drug application submitted to The Food and cialis brand Drug Administration
KRN5500 is a novel, spicamycin-derived, non-opioid-non-narcotic intravenous pain therapeutic with promising clinical trial results in patients with chemotherapy-induced peripheral neuropathy (CIPN)
More than 70% of patients treated with taxane-class or platinum-class chemotherapeutic agents; at least 25% of those treated with vinca-class agents; and significant numbers of those treated with Thalomid®, Revlimid®, Velcade®, and a variety of other cancer drugs experience CIPN, which can be disabling and cheap cialis online adversely affect quality of life.
There is presently no FDA-approved drug for CIPN.
In October, 2011, the U.S. FDA granted KRN-5500 Fast Track designation for CIPN, an indication with a market potential estimated at $2.5B.
Summary of Phase 2a clinical trial results:
The stock is trading in a manner that hints at positive news concerning the buying viagra with no prescription Orphan Drug status application.
The above chart is forming a cup and cialis samples handle breakout pattern with resistance at $1.20. Once past this level, the near term price target indicates a test of the buying viagra online cheap us prior high of $1.38. Measuring the zithromax online overnight cup and handle break indicates a move over $2 in the coming months. I predicted a move to $0.98 on my live online show as a good entry point before beginning to break out -- The price hit $0.97, and then began to move back upwards. I am setting a price target opinion of $1.35 to $1.45 for the short term.
Disclosure: Author Scott Matusow is Long DARA.